Background-Inflammation has been closely linked to auto-immunogenic processes in atherosclerosis. Plasmacytoid dendritic cells (pDCs) are specialized to produce type-I interferons in response to pathogenic single-stranded nucleic acids, but can also sense self-DNA released from dying cells or in neutrophil extracellular traps complexed to the antimicrobial peptide Cramp/LL37 in autoimmune disease. However, the exact role of pDCs in atherosclerosis remains elusive. Methods and Results-Here we demonstrate that pDCs can be detected in murine and human atherosclerotic lesions. Exposure to oxidatively modified low-density lipoprotein enhanced the capacity of pDCs to phagocytose and prime antigen-specific T cell responses. Plasmacytoid DCs can be stimulated to produce interferon-␣ by Cramp/DNA complexes, and we further identified increased expression of Cramp and formation of neutrophil extracellular traps in atherosclerotic arteries. Whereas Cramp/DNA complexes aggravated atherosclerotic lesion formation in apolipoprotein E-deficient mice, pDC depletion and Cramp-deficiency in bone marrow reduced atherosclerosis and anti-double-stranded DNA antibody titers. Moreover, the specific activation of pDCs and interferon-␣ treatment promoted plaque growth, associated with enhanced anti-double-stranded-DNA antibody titers. Accordingly, anti-double-stranded DNA antibodies were elevated in patients with symptomatic versus asymptomatic carotid artery stenosis. Conclusions-Self-DNA (eg, released from dying cells or in neutrophil extracellular traps) and an increased expression of the antimicrobial peptide Cramp/LL37 in atherosclerotic lesions may thus stimulate a pDC-driven pathway of autoimmune activation and the generation of anti-double-stranded-DNA antibodies, critically aggravating atherosclerosis lesion formation. These key factors may thus represent novel therapeutic targets. (Circulation. 2012;125:1673-1683.)
IFN-␣ expression, which in turn amplified inflammatory cytokine responses and immune cell activation, 3, 4 suggesting proatherogenic functions of this DC subset. Conversely, pDCs can also exert tolerogenic functions, as shown in a vascularized graft model. 12 Thus, the role of pDCs in atherosclerosis remains to be conclusively explored.
Methods

Mouse Models
Apolipoprotein E-deficient (Apoe Ϫ/Ϫ ), low-density lipoproteindeficient (Ldlr Ϫ/Ϫ ), lymphocyte-deficient (Rag1 Ϫ/Ϫ ), and wild-type mice (C57BL/6J) were purchased from the Jackson Laboratory. At 6 to 8 weeks, female mice were subjected to a high-fat diet (HFD, 21% fat, 0.15% cholesterol, Altromin). Plasmacytoid DC depletion in Apoe Ϫ/Ϫ mice was performed by i.v. injection of the monoclonal antibody PDCA1 13, 14 (500 g/mouse, Miltenyi Biotech) or an isotype control antibody (500 g/mouse, BioXcell) at day 1 and day 7 after the initiation of HFD feeding. PDCA1 antibody treatment efficiently depleted pDCs in lymph nodes, spleen, and bone marrow while not altering cDC, T-cell or B-cell frequencies, as assessed by fluorescence-activated cell-sorting (FACS) analysis (online-only Data Supplement Figure I ). Some mice were injected with oligonucleotide CpG 1585 (25 g/mouse, Inovagen) complexed to DOTAP (15 g/mouse, Roche) or with DOTAP or PBS alone 3 times/week for 4 weeks. Some mice were i.p. injected with murine IFN-␣ (100 000 U, HyCultBiotec) 2 times/week for 4 weeks. Some Apoe Ϫ/Ϫ mice were i.v. injected with Cramp/DNA complexes 15 3 times/week for 4 weeks, together with receiving PDCA1 or isotype control antibody. Female Ldlr Ϫ/Ϫ mice were irradiated and reconstituted with Cramp Ϫ/Ϫ 16 or Cramp ϩ/ϩ bone marrow 17 and after recovery were placed on HFD for 4 weeks. Some Apoe Ϫ/Ϫ mice were treated with Cramp (i.p. 100 g/mouse), DNase I (i.v., 120 U/mouse, Sigma), or both 3 times/week for 4 weeks. No changes in cholesterol or triglyceride serum levels, as assessed by EnzyChrom high-density lipoprotein and LDL/VLDL Assay Kit (BioAssay Systems), were observed between groups of mice (online-only Data Supplement Table I ). Rag1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice were fed a HFD for 12 weeks. High-fat diet-fed lysozyme M (lys)-enhanced green fluorescent protein (EGFP) Apoe Ϫ/Ϫ mice 18 were i.v. injected with 250 L of liposomes containing clodronate 19 1 day before and propidium iodide (2 g/mL final concentration) immediately before imaging. Experiments were approved by local authorities.
Atherosclerotic Lesion Quantification and Immunohistochemistry
The extent of atherosclerosis was assessed in aortic roots and in aortas by staining for lipid depositions with Oil-red-O 17 . The relative content of macrophages and the localization of pDCs, Cramp, and plaque immunoglobulin Gs (IgGs) were determined by immunofluorescence staining. Nuclei were counterstained by 4Ј,6-Diamidino-2phenylindol (DAPI). Human carotid artery specimens were obtained from autopsy or vascular surgery. The location of blood dendritic cell antigen-2 (BDCA2) and LL37 expression in the plaque was determined using standard immunohistochemistry techniques. 20 
DC Isolation and Stimulation In Vitro
Plasmacytoid DCs were isolated from spleens of C57BL/6J mice using the Plasmacytoid Dendritic Cell Isolation Kit II (Miltenyi Biotec). Alternatively, pDCs were sorted (FACSAria, BD Bioscience) from bone marrow of C57BL/6J with an antibody cocktail against CD45, SiglecH, and CD45RA (B220). Isolated pDCs were stimulated with oxidatively modified low-density lipoprotein (ox-LDL) or di-oxLDL (50 g/mL), Cramp (50 g/mL, Innovagen), DNA (10 g/mL, mouse C57Bl6/6J female genomic DNA, Zyagen), CpG 1585 (5 g/mL, Invivogen), or Cramp/DNA complexes 15 
Antigen-Specific T-Cell Proliferation In Vivo
CD4 ϩ T cells were isolated from the spleen of OT-II mice (CD4 T cell isolation kit, Miltenyi), and labeled with CFSE (Fluka). Plasmacytoid DCs prestimulated with oxLDL (50 g/mL), CpG1585 (5 g/mL), or a combination of both were pulsed for 45 minutes with OVA 323 to 339 peptide (30 g/mL). Untreated pDCs were used as control. For in vivo studies, 5ϫ10 6 CD4 ϩ CFSE-labeled OT-II cells were i.v. injected into C57BL/6 recipient mice. One day later, 1ϫ10 5 untreated or treated OVA-2 peptide-pulsed pDCs were injected into the footpad. After 3 days, T-cell proliferation was analyzed by CFSE dye dilution in peripheral lymph nodes of recipient mice by flow cytometry.
Flow Cytometry and ELISA
Lymph nodes and spleen were dissociated into single-cell suspensions using collagenase D, and aortas digested using Liberase III (Roche). Staining for flow cytometric analysis was conducted using combinations of specific antibodies from eBiosciences, Miltenyi, and BD Bioscience. Data were acquired using a FACSCantoII (BD Bioscience), and results analyzed by FlowJo software (Tree Star). Cell culture supernatants or sera were analyzed by ELISA detecting IFN␣ (VeriKine Mouse Interferon-Alpha ELISA Kit, PBL Laboratories), dsDNA (Mouse antidsDNA Kit, Alpha Diagnostic), and antidsDNA antibodies (Varelisa dsDNA Antibody ELISA, Phadia) according to the manufacturer's protocol; antidsDNA Ab (ϩ) Ͼ55 IU/mL. Reciprocal serum dilutions to determine antinuclear antibodies in humans were performed by indirect immunofluorescence on HEp-2 substrate according to the manufacturer's instructions (ANA IFT IgG Kit, Viramed); (ϩ) Ͼ1:160. Antibodies to malondialdeyhdemodified (MDA)-LDL and oxLDL were measured by chemiluminescent ELISA. 21
Quantitative Real-Time Polymerase Chain Reaction
RNA was isolated from aortas with the ZR RNA MicroPrep RNA isolation kit (Zymo Research), and complementary DNA was reverse transcribed from total RNA (Promega). Real-time polymerase chain reaction analysis was performed using SYBRGreen (Fermentas) and specific primer pairs. Amplification was performed in duplicate using a 7900 HT fast real-time polymerase chain reaction system (Applied Biosystems).
Two-Photon Microscopy
In vivo 2-photon microscopy of exposed carotid arteries was performed as described. 22 In short, the exposed left carotid artery was visualized using an upright Olympus FV1000MPE 2-photon microscope system equipped with a 1.05 water dipping objective. A pulsed Ti-Sapphire laser (MaiTai DeepSee, Spectra Physics) was tuned to 810 nm for visualization of second harmonic generation (SHG) signal of collagen, green fluorescent protein (GFP), and propidium iodide. Emitted fluorescent signals were detected with 3 photomultiplier tubes. Series of subsequent xy-sections (256ϫ256 pixels) were obtained over time at an acquisition rate of 4Hz. All image processing was performed using Image-Pro 3D Analyzer 7.0 (Media Cybernetics).
Human Microarray Data Evaluation
Seventeen atherosclerotic tissue samples from atherosclerotic carotid artery segments (9 from early and 8 from advanced lesions) from the Maastricht Pathology Tissue Collection were processed as described. 23 Total RNA was isolated and purified and RNA quality determined using a 20100 Bioanalyzer (Agilent Technologies). Samples with an RNA integrity number of 5 were further processed (mean RNA integrity numberϭ7.8). Double-stranded complementary DNA was synthesized (One-Cycle Target Labeling Kit, Affymetrix) and used as a template for the preparation of biotin-labeled complementary RNA using the GeneChip IVT Labeling Kit (Af-fymetrix). Biotin-labeled complementary RNA was hybridized in duplicates to the Human Genome U133 Plus 2.0 Array (Affymetrix), washed, and stained. Arrays were laser scanned with the GeneChip Scanner 3000 (Affymetrix). Data were quantified using GCOS 1.2 (Affymetrix), and the resulting CEL files processed in R. The resulting expression set was analyzed by limma. After Bayesian smoothing of the SEs of the estimated log-fold changes, the transcripts of interest were reported as log2 fold changes, average expression, and Benjamin-Hochberg false discovery rate adjusted P values.
Study Patients
A total of 30 patients with advanced carotid artery stenosis (Ͼ70%, determined by measuring the peak systolic velocity by ultrasonography) were included in this study. Asymptomatic patients (nϭ15) without neurological symptoms were diagnosed at the Vascular Centre of the Technical University Munich; symptomatic patients (nϭ15) displaying neurological symptoms (transient ischemic attack or nondisabling stroke) were assigned from the Institute of Neurology of the hospital Klinikum rechts der Isar, Munich. Patients with chronic kidney disease, diabetes mellitus, autoimmune disease, and ongoing steroid or other immunosuppressive medication were excluded from the study. Blood sampling was performed within 2 days preceding surgical intervention.
Statistics
Unpaired Student t tests were used to compare Cramp messenger RNA (mRNA) and dsDNA antibody titers between control and HFD-fed Apoe Ϫ/Ϫ mice, dsDNA antibody titers between IgG-and PDCA1-treated Apoe Ϫ/Ϫ mice, and dsDNA antibody titers and plaque size between Cramp ϩ/ϩ ‹Ldlr Ϫ/Ϫ and Cramp Ϫ/Ϫ ‹Ldlr Ϫ/Ϫ mice. Mann Whitney tests were applied to compare pDC frequencies and IFN-␣ levels between control and HFD-fed Apoe Ϫ/Ϫ mice, Di-oxLDL uptake in vitro, plaque sizes between IgG-and PDCA1-treated Apoe Ϫ/Ϫ mice, and dsDNA antibody titers between patients with asymptomatic versus symptomatic carotid artery stenosis. ANOVA 1-way analysis of variance followed by the Tukey multiple comparison post tests were used for comparing SigH and IFN␣ mRNA expression between control and HFD-fed Apoe Ϫ/Ϫ mice, CD36 expression, OVAII-488 uptake, and IFN-␣ secretion by pDCs in vitro, plaque size between controls, CpG, and CpGϩPDCA1treated, or Cramp and CrampϩDNAse-treated Apoe Ϫ/Ϫ mice. Kruskal-Wallis tests were applied to compare T-cell proliferation in vivo and plaque size between controls, Cramp/DNAϩisotype, and Cramp/DNAϩPDCA1-treated Apoe Ϫ/Ϫ mice. Differences where P was Ͻ0.05 were considered statistically significant.
Results
Plasmacytoid DCs are not only present in lymph nodes and spleen (online-only Data Supplement Figure II ) but could also be detected in atherosclerotic lesions. As shown by staining for Siglec-H ϩ , single pDCs were localized to the plaque shoulders and areas bordering the necrotic core in aortic root plaques of Apoe Ϫ/Ϫ mice fed a HFD for 12 weeks ( Figure 1A ). Compared with healthy wild-type Apoe ϩ/ϩ mice or Apoe Ϫ/Ϫ mice on normal chow, diet-fed Apoe Ϫ/Ϫ mice displayed higher frequencies of aortic PDCA1 ϩ pDCs ( Modified lipoproteins (eg, oxLDL) are deposited in the arterial wall during atherogenesis 1,2 and can be taken up by CD11c ϩ DCs in the vessel wall. 24 Moreover, oxLDL has been found to induce the upregulation of scavenger receptors on DCs. 25 We therefore tested the capacity of pDCs to take up and to respond to oxLDL. Indeed, sorted pDCs were capable of taking up di-labeled oxLDL (Figure 2A ). Similar to prototypical TLR7/TLR9 activation with CpGs, 6 exposure to oxLDL selectively enhanced surface expression of CD36 (Figure 2A ), which has been implicated in its phagocytosis. 26 However, oxLDL did not alter surface expression of CD68, SR-A, MHC-II, and CD86 nor secretion of IFN-␣ protein, whereas MHC-II and CD86 expression increased after CpG stimulation (online-only Data Supplement Figure IIIA and data not shown).
Mature pDCs are capable of initiating T-cell responses. 27 Accordingly, we observed that OVA-2-loaded pDCs but not unpulsed pDCs induced antigen-specific proliferation of OT-II CD4 ϩ T cells in vivo. Interestingly, T-cell proliferative responses were potentiated by pretreatment of pDCs with oxLDL, amounting to a response resembling that after pretreatment with CpGs ( Figure 2B ). Combining oxLDL and CpGs did not yield additive effects (data not shown). A robust IFN-␣ protein secretion was detectable in CpG-stimulated pDC-T-cell cocultures in vitro but not in supernatants of T cells cocultured with pDCs or after addition of oxLDL (online-only Data Supplement Figure IIIB) . Notably, oxLDL treatment enhanced phagocytosis of the fluorescently labeled OVA-2 antigen in a manner similar to that of CpGs ( Figure  2C ), implying that the enhanced phagocytic capacity on exposure to oxLDL may boost pDC-driven immune responses in the context of atherosclerosis.
To scrutinize the role of pDCs in atherosclerotic lesion development, Apoe Ϫ/Ϫ mice fed a HFD were injected with a pDC-depleting PDCA1 or isotype control antibody. After 4 weeks, a substantial reduction in plaque size in the aortic root and aorta as well as a decrease in lesional macrophage frequencies was observed in pDC-depleted Apoe Ϫ/Ϫ mice compared with IgG-injected Apoe Ϫ/Ϫ controls ( Figure 3A , online-only Data Supplement Figure IVA ). This decrease in plaque size was associated with a significant reduction in IFN-␣ serum levels in Apoe Ϫ/Ϫ mice depleted of pDCs compared with IgG-injected Apoe Ϫ/Ϫ controls (10.5Ϯ4.5 versus 44.1Ϯ11.7 pg/mL, respectively, PϽ0.05). Conversely, aggravated lesion formation and macrophage content was observed in diet-fed Apoe Ϫ/Ϫ mice injected with IFN-␣ for 4 Figure IVC) . These effects were abrogated in Apoe Ϫ/Ϫ mice additionally depleted of pDCs by PDCA1 antibody injections ( Figure 3B , online-only Data Supplement Figure IVC) . These findings clearly demonstrate that pDCs and their effector cytokine IFN-␣ drive early lesion development.
Breakdown of tolerance to otherwise inert self-DNA fragments released by dying cells 6 (eg, in psoriasis) can be triggered by Cramp, an antimicrobial peptide rapidly released from neutrophil granules, 28, 29 which binds self-nucleic acids to form complexes that trigger TLR7/TLR9 activation and type-I IFN secretion by pDCs. 11, 15 Also, NETs containing self-DNA and antimicrobial peptides released by activated neutrophils during cell death, a process termed "NETosis," can trigger pDC activation. 7, 10, 30 Like CpGs and dsDNA containing CpG motifs 15 An increased expression of Cramp mRNA ( Figure 4B ) and Cramp protein (23.1Ϯ6.9 versus 0% staining/plaque area) was observed in the vessel wall of diet-fed Apoe Ϫ/Ϫ mice compared with healthy Apoe Ϫ/Ϫ controls. Cramp was detected in the vicinity of segment-nucleated neutrophils within atherosclerotic lesions ( Figure 4C ), likely reflecting neutrophil accumulation during early lesion development, 17 and in colocalization with small DNA fragments in necrotic core areas ( Figure 4C ). Using 2-photon microscopy of atherosclerotic carotid arteries, we furthermore revealed the presence of NETs in atherosclerotic carotid arteries and within plaques of monocyte-depleted Lysm EGFP/EGFP Apoe Ϫ/Ϫ mice carrying only fluorescent neutrophils ( Figure 4D , data not shown). Extracellular NETs were detected by use of propidium iodide, a vital cell-impermeable nuclear marker that stained clouds of DNA in the vicinity of EGFP ϩ neutrophils at atherosclerotic sites and could be observed as early as 2 weeks after the initiation of diet (online-only Data Supplement Table II) . Notably, the injection of Cramp/DNA complexes into Apoe Ϫ/Ϫ mice promoted an enhanced atherosclerotic lesion formation in the aortic root when compared with controlinjected Apoe Ϫ/Ϫ mice, which was averted in mice additionally depleted of pDCs by PDCA1 antibody treatment ( Figure  4E ). These data clearly indicate that Cramp/self-DNA complex-mediated pDC activation drives atherosclerotic plaque development. Thus, Cramp-complexed self-DNA derived from neutrophil-expelled NETs and dying plaque cells may contribute to breakdown of tolerance to self-DNA. [7] [8] [9] [10] 31 In systemic lupus erythematosus, patients were found to develop autoantibodies to self-DNA and antimicrobial peptides in NETs, indicating that these complexes serve as auto-antigens to trigger B-cell activation and the generation of anti-DNA-specific antibodies. 7 We here demonstrate that serum antidsDNA antibody titers were increased in hyperlip- idemic Apoe Ϫ/Ϫ mice compared with healthy control Apoe Ϫ/Ϫ mice ( Figure 5A ). Conversely, antidsDNA antibody titers were reduced in Apoe Ϫ/Ϫ mice treated with PDCA1 antibody to deplete pDCs compared with IgG-injected controls. Furthermore, antidsDNA titers were elevated in IFN-␣and CpG-treated Apoe Ϫ/Ϫ mice but not in CpG-injected mice depleted from pDCs (online-only Data Supplement Figure  VD and Figure 5B ). Interestingly, humoral responses to other known auto-antigens in atherosclerosis, namely MDA-LDL and oxLDL, were not affected by pDC depletion, as shown by unaltered IgG antibody concentrations toward these antigens in PDCA1 versus control-treated Apoe Ϫ/Ϫ mice (online-only Data Supplement Figure VI ). This indicates that pDCs specifically promote dsDNA antibody formation in early atherosclerosis. However, increased MDA-LDL and oxLDLspecific IgG antibody levels were observed in CpG-treated Apoe Ϫ/Ϫ mice but not in mice additionally treated with PDCA1 antibody (online-only Data Supplement Figure VI ). This suggests that strong pDC activation also promotes unspecific amplification of humoral immune responses to antigens in atherosclerosis, likely because of abundant type-I IFN production. 32, 33 Notably, diminished antidsDNA antibody titers were observed in Ldlr Ϫ/Ϫ mice reconstituted with Cramp Ϫ/Ϫ versus Cramp ϩ/ϩ bone marrow ( Figure 5C ) together with a protection from atherosclerotic lesion formation ( Figure 5D ) and a reduction in macrophage content in the aortic root (19.2Ϯ2.4 versus 30.2Ϯ3.5%, respectively, PϽ0.05). Conversely, treating mice with Cramp promoted atherosclerotic plaque growth compared with control-treated Apoe Ϫ/Ϫ mice but was ineffective in mice additionally treated with DNAse to degrade extracellular DNA ( Figure 5E ), indicating that proatherogenic functions of Cramp require the association with extracellular self-DNA.
Immunogenic DNA-containing immune complexes have been shown to contain LL37 and to further enhance pDC activation. [7] [8] [9] [10] This concurs with results that serum of Apoe Ϫ/Ϫ mice containing high levels of antidsDNA antibody titers but not serum containing low titers significantly increased IFN-␣ production in pDCs ( Figure 5F ), leaving MHC-II expression unaltered (online-only Data Supplement Figure VE) . Conversely, serum derived from atherosclerotic Rag1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice did not elicit IFN-␣ responses in pDCs (data not shown). Although we refrained from purifying IgG-containing immune complexes because of the limited amount of serum available from mice, these data suggest that IgG complexes containing DNA in serum may contribute to pDC activation. Interestingly, abundant IgG deposits could be detected in atherosclerotic plaques of diet-fed Apoe Ϫ/Ϫ mice, predominantly in the vicinity of necrotic plaque areas ( Figure  5G ). Thus, auto-immunogenic complexes deposited within lesions in vivo may contribute to the pathogenic insult in atherosclerosis.
To assess whether these mechanisms may also be relevant to human disease, differential expression analysis was performed on gene expression microarrays from human atherosclerotic lesions. Comparisons of early and advanced carotid artery specimens revealed an increase in expression of pDC markers in advanced versus early lesions (online-only Data Supplement Table III) . Accordingly, BDCA2 ϩ pDCs and LL37 were detected in advanced human carotid plaques but less frequently in early lesions ( Figure 6A ). Negative controls showed no staining (data not shown). This suggests that the presence of pDCs correlates with plaque progression in human atherosclerosis. Furthermore, reciprocal serum dilutions to determine auto-antibodies directed against nuclear antigens revealed average titers of 1:190.0Ϯ99.1 in asymptomatic patients but 1:871.1Ϯ548.4 in symptomatic patients (nϭ8 -9, Pϭ0.1336). Moreover, elevated levels of circulating antidsDNA antibodies were observed in patients with symptomatic compared with asymptomatic carotid artery stenosis ( Figure 6B) ; age, risk factors, and medication were not different between patient groups (online-only Data Supplement Table IV ). 
Discussion
In recent years, it has become evident that a number of specialized immune cell populations contribute to atherogenesis. Besides monocytes/macrophages, several T-cell subsets, conventional DCs, and neutrophils have emerged as critical players in atherosclerosis. 1, 17 The role of pDCs, however, has remained elusive to date. Here we provide the first evidence that a pDC-dependent pathway of autoimmune activation critically drives early atherosclerotic lesion formation.
Plasmacytoid DCs have previously been found in carotid artery plaques, primarily in the plaque shoulder region. 4 In addition, reduced circulating pDC counts have been described in patients with coronary artery disease, which may correspond to their enhanced accumulation within atherosclerotic lesions. 34 Accordingly, we observed an accumulation of pDCs in murine and human atherosclerotic plaques but not in other secondary lymphoid organs (not shown) and an increased expression of pDC markers in advanced versus early human atherosclerotic carotid artery lesions.
Described as inflammatory amplifiers, plaque-residing pDCs were shown to respond to CpGs (containing motifs typically found in microbial DNA) with an enhanced IFN-␣ expression, which in turn amplified inflammatory TLR4, TNF-␣, IL-12, and matrix metalloproteinase-9 expression by myeloid DCs and cytolytic T-cell functions, and which correlated with plaque instability. 3, 4 In order to scrutinize the role of pDCs in atherosclerosis, we employed a specific pDC-depleting antibody. In line with the notion that pDCs exert proinflammatory effects, we here demonstrate that pDCs and their activation critically drive atherosclerotic lesion formation. Administration of a PDCA1 antibody to deplete pDCs protected from lesion formation. Conversely, stimulation of Apoe Ϫ/Ϫ mice with type A CpGs promoted plaque growth in a pDC-dependent manner, as revealed by abrogating CpG-induced lesion formation by the additional depletion of this cell type. Of note, treatment of Apoe Ϫ/Ϫ mice with type-B CpGs, known to activate B cells rather than pDCs, was previously shown to not affect atherosclerotic lesion formation. 35 These findings, furthermore, corroborate that activating pDCs rather than other cell types by type-A CpGs (used in our study) mediates enhanced plaque growth. Although reduced IFN-␣ serum levels could be observed in pDC-depleted mice, administration of IFN-␣ aggravated lesion formation and macrophage plaque content in Apoe Ϫ/Ϫ mice, extending findings that treatment with IFN-␣ or IFN-␤ accelerates atherosclerotic lesion formation and that IFN-␤ promotes macrophage accumulation in plaques. 36, 37 Plasmacytoid DC-derived type-I IFNs can likewise also activate other immune cells, such as cDCs and B cells, to promote autoimmunity, 38 which may also be relevant in atherosclerosis.
Plasmacytoid DCs have also been shown to exert tolerogenic functions; in a vascularized graft model, pDC depletion or prevention of pDC lymph-node homing inhibited regulatory T-cell differentiation and tolerance induction whereas adoptive transfer of tolerized alloantigen-presenting pDCs prolonged graft survival. 12 In the present study, we clearly demonstrate that pDCs exert proatherogenic functions during early lesion formation.
The responsiveness of pDCs to viruses or bacterial infections, as epitomized by treatment of Apoe Ϫ/Ϫ mice with CpGs, may corroborate the link between atherosclerosis and chronic infection burdens and possibly the inflammatory activation of vulnerable plaques in response to acute infections. 3 However, nucleotides released from necrotic or apoptotic cells may also be prone to binding TLR7/TLR9 and to inducing IFN-␣ production by pDCs in the presence of antimicrobial peptides released from inflammatory cells. 39 For instance, self-DNA fragments released by dying cells (eg, in psoriasis) can be bound by Cramp, an antimicrobial peptide rapidly released from neutrophil granules, 6, 28, 29 to form complexes that trigger TLR7/TLR9 activation and type-I IFN secretion. 11, 15 Similarly, NETs, web-like structures containing self-DNA and antimicrobial peptides, can trigger pDC activation. 10, 11, 30 These factors may also be present in atherosclerosis plaques. Extending findings in humans, where an increased expression of LL37 has been described in atherosclerotic carotid artery plaques compared with normal arteries in colocalization with macrophages and endothelial cells, 40 we here observed increased Cramp expression in atherosclerotic Apoe Ϫ/Ϫ arteries. Cramp protein was detected in colocalization with DNA fragments in plaque necrotic core areas, suggesting that Cramp/self-DNA complexes may form in atherosclerosis. Notably, injection of Cramp promoted atherosclerotic plaque growth dependent on the presence of extracellular self-DNA. Thus, the formation of Cramp/self-DNA complexes may contribute to pDC activation and enhanced atherosclerosis, as exemplified by their capability of triggering IFN-␣ secretion by pDCs in vitro and their pDC-dependent acceleration of lesion formation in Apoe Ϫ/Ϫ mice in vivo. Cramp may be released by neutrophils recruited during early lesion development, 17, 29, 41 as implied by its detection in the vicinity of segment-nucleated neutrophils in plaques. In addition, we unprecedentedly observed the formation of NETs in atherosclerotic carotid arteries. These Cramp/self-DNA complexes contained in neutrophilexpelled NETs may further trigger pDC activation. 10, 11 Cytokines including IFN-␣ may reciprocally prime neutrophils to allow the formation of NETs, 42 thus driving positive feedback amplification.
Interestingly, oxLDL enhanced phagocytosis of pDCs and their capacity to prime antigen-specific T-cell responses while not directly contributing to IFN-␣ responses or costimulatory molecule upregulation. Exposure to oxLDL within plaques 1,2 may thus boost uptake of antigenic complexes by pDCs and their activation in atherosclerosis.
Interestingly, diminished antidsDNA antibody titers were observed in Ldlr Ϫ/Ϫ mice reconstituted with Cramp Ϫ/Ϫ versus Cramp ϩ/ϩ bone marrow, together with a protection from atherosclerotic lesion formation. Moreover, antidsDNA antibody titers but not antibodies toward MDA-or oxLDLderived antigens were found to be decreased in pDC-depleted mice whereas antidsDNA antibody titers were enhanced in Apoe Ϫ/Ϫ mice stimulated with CpGs or treated with IFN-␣. These data intriguingly suggest that Cramp-dependent breakdown of tolerance to self-DNA may stimulate pDCs and IFN-␣ production, contributing to the formation of antidsDNA antibodies. This hypothesis may also be in line with findings that IFN-␣ supports humoral immunity (eg, by enabling B cells to undergo isotype switching and to mature into antigen-secreting cells). 32 The comparatively low levels of such autoimmune activity may be related to a locally confined pattern of this mechanism. Prototypical pDC stimulation and large amounts of IFN-␣ in CpGtreated Apoe Ϫ/Ϫ mice may in turn explain increased antibodies also toward other known antigens in atherosclerosis, namely MDA or oxLDL. It remains to be determined if self-DNA complexed to Cramp may in addition also directly active B cells via TLR9, which can be similarly enhanced by IFN-␣. 38 In line with previous work, we have detected the presence of IgG deposits within atherosclerotic arteries. 43 Likewise, antidsDNA antibodies may also be deposited within plaques. It was recently shown that these immune complexes contain self-DNA as well as antimicrobial peptides and can effectively trigger pDC activation and IFN-␣ production. [7] [8] [9] [10] [11] 31 In accordance with this, serum of Apoe Ϫ/Ϫ mice containing high levels of antidsDNA antibody titers but not serum containing low titers significantly increased IFN-␣ production in pDCs in vitro whereas serum derived from atherosclerotic Rag1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice did not elicit IFN-␣ responses in pDCs. Thus, antidsDNA antibodies, generated as a consequence of pDC activation, may contribute to the pathogenic insult in atherosclerosis.
Although values may be of limited clinical relevance in a rheumatological context, increased levels of circulating an-tidsDNA antibodies in atherosclerotic Apoe Ϫ/Ϫ mice, as well as in patients with symptomatic and more advanced atherosclerosis, may support a pathogenic role of antidsDNA antibodies. Importantly, elevated anti-nuclear antibody titers were associated with decreased carotid elasticity in young Finns and were postulated to participate in the development of early atherosclerosis. 44 Moreover, in an animal model of systemic lupus erythematosus with enhanced antibody titers against dsDNA, atherosclerotic lesion formation was accelerated. 45 Chronically increased IFN-␣ levels and circulating antids-DNA antibody titers in patients with psoriasis and systemic lupus erythematosus 6 may likewise predispose for an increased risk to develop hyperlipidemic atherosclerosis. 46 Collectively, our data provide evidence for a hitherto unrecognized pathway of autoimmune activation in atherosclerosis, driven by pDCs that sense self-DNA fragments complexed to Cramp and contribute to the formation of antinuclear antibodies. Exposure to oxLDL during atherogenesis may amplify the immunogenicity of pDCs by enhancing phagocytosis and priming of antigen-specific T-cell responses. Targeting pDC activation may thus constitute a promising approach to limit atherosclerotic lesion development.
